John C. Jacobs - 02 Mar 2026 Form 4/A - Amendment Insider Report for NOVAVAX INC (NVAX)

Role: President and CEO, Director
Signature: /s/ Mark J. Casey, Attorney-in-Fact
Issuer symbol: NVAX
Transactions as of: 02 Mar 2026
Net transactions value: $0
Form type: 4/A - Amendment
Filing time: 09 Mar 2026, 18:08:11 UTC
Date Of Original Report: 03 Mar 2026
Previous filing: 03 Mar 2026
Next filing: 05 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Jacobs John C	President and CEO, Director	21 FIRSTFIELD ROAD, GAITHERSBURG	/s/ Mark J. Casey, Attorney-in-Fact	09 Mar 2026	0001820836

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NVAX	Non-Statutory Stock Option NQ	Award		+551,500		$0.000000^*	551,500	02 Mar 2026	Common Stock	551,500	$10.11	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This Form 4/A has been filed solely to amend the exercise price as originally reported in Column 2 and price of derivative security as originally reported in Column 8 of Table II of the Reporting Person's Form 4 filed on March 3, 2026. All other information remains unchanged from the March 3, 2026 filing.
F2	One quarter (1/4) of the shares subject to this option granted under the Plan vest on the first anniversary of March 2, 2026, and the remaining three-quarters (3/4) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.